EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Amoy Diagnostics Co Ltd (300685) fair value: what the stock is really worth

As of Sep 22, 2026: fair value of Amoy Diagnostics Co Ltd ¥21.92, price ¥19.93, upside +10.0%, quality 77 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · CN · ISIN CNE1000034D3

AD Broad data Sep 24, 2026

Amoy Diagnostics Co Ltd

300685 · SHE

Quality WatchlistQuality growthA strong company, but the current price is close to Fair Value.

·Fair value ¥21.92 · Fairly valued (+10%)
✓Quality 77/100
✓Healthy Growth (revenue 5y +10.5 %/yr)
✓Highly profitable · 30.0% net margin (TTM)
✓Low debt · generates free cash flow
·2.26% dividend yield
✓Ranks above peers (10/14)
✓Wide moat 79/100
Watch Amoy Diagnostics Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥55.60 ¥15.08 Fair Value ¥21.92 Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range ¥15.08 – ¥55.60 · fair‑value band ¥15.17 – ¥36.81 · the ¥19.93 price screens below the ¥21.92 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Amoy Diagnostics Co in your weekly email

Every Wednesday you see whether Amoy Diagnostics Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally.

Show more

Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx comprehensive panel, a sequencing-based test capable of detecting a range of alterations; AmoyDx HRD complete panel, detects genetic aberrations across HRR genes and HRD status; AmoyDx master panel, a comprehensive genomic profiling assay; AmoyDx BRCA Pro panel, covers various protein coding regions, intron/exon boundaries, select introns, and UTR regions of the BRCA1 and BRCA2 genes; AmoyDx handle classic NGS panel, detects multiple gene mutations in cancer patients for treatment; and AmoyDx essential NGS panel, detects EGFR, ALK, ROS1, RET, KRAS, NRAS, PIK3CA, BRAF, HER2, and MET genes in patients with non-small cell lung cancer and colorectal cancer using FFPE or liquid biopsy samples. It also provides AmoyDx handle HRR NGS panel for detection of somatic and germline variants; AmoyDx pan lung cancer PCR panel, a tissue-based real-time qPCR assay for in vitro diagnostics; AmoyDx myeloid blood cancer panel; AmoyDx comprehensive panel solutions; AmoyDx PD-L1 (E1L3N) assay; and AmoyDx handle melanoma NGS panel solutions. In addition, the company offers ALK gene fusions and ROS1 gene fusions, multi-gene mutations, EML4-ALK fusion gene, EGFR/ALK/ROS1 mutations, MET mutation, HER2 mutation, RET gene fusions, KRAS mutation, KRAS/NRAS mutations, NRAS mutation, KRAS/NRAS/BRAF mutations, BRAF mutation, PIK3CA five mutations, microsatellite instability, PIK3CA mutation, human papillomavirus genotyping, JAK2 mutation, TERT/HRAS mutations, EGFR 29 mutations, EGFR mutation, ROS1 gene fusions, NTRK gene fusions, BRAF V600 mutations detection kits, as well as DNA and RNA extraction kits under the Super-ARMS and AmoyDx names. The company was founded

Stock analysis

Amoy Diagnostics Co Ltd (300685) currently trades at ¥19.93, while our model-based Fair Value estimate is ¥21.92, implying the stock looks roughly 9.1% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of ¥27.04 per share, and 9 of the 24 models we run sit above the ¥19.93 price.

Bear case: the Asset-Based group reads lowest at ¥3.53, and 15 of the 24 models stay below the price. Evidence for this calculation is high.

Scenario range: ¥15.17 (bear) to ¥36.81 (bull), the price of ¥19.93 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 77/100 (high quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Amoy Diagnostics Co Ltd reported revenue of 1.2B CNY in FY2025 versus 917M CNY in FY2021, a compound +6.9%/yr. Reported net income was 358M CNY in FY2025, compounding +10.6%/yr from FY2021.

Key figures

Market cap 7.9B CNY (≈ $1.2B) · P/E ratio 22.4 · P/S ratio 6.69 · EPS (TTM) ¥0.8900 · Dividend yield 2.3% · Net margin 29.9% · Return on equity 17.9% · Return on assets (EBIT) 16.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (medium confidence).

What moves the price

The share trades about 14% below its 52-week high and 23% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 10%, 300685 screens cheaper than that median.

Fair Value models

Bear ¥15.17 Fair Value ¥21.92 Bull ¥36.81
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (¥0.3219 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF ¥12.54 ¥17.58 ¥31.79 78
Growth DCF ¥11.96 ¥18.57 ¥30.32 77
EPV ¥10.20 ¥11.25 ¥12.13 74
All 24 models by family
DCF Models
FCF DCF ¥12.54 ¥17.58 ¥31.79 78
Owner Earnings ¥13.74 ¥25.81 ¥48.20 73
5Y Revenue Exit ¥10.27 ¥16.03 ¥27.38 71
5Y EBITDA Exit ¥14.10 ¥24.13 ¥42.84 72
5Y P/E Exit ¥15.69 ¥30.97 ¥51.05 68
10Y Revenue Exit ¥10.70 ¥18.34 ¥25.62 66
10Y EBITDA Exit ¥13.42 ¥25.22 ¥47.27 65
10Y P/E Exit ¥14.46 ¥28.08 ¥52.26 61
Earnings-Based
Graham-Dodd ¥6.24 ¥43.51 ¥61.05 63
Lynch FV ¥13.89 ¥19.84 ¥25.80 61
PEG = 1.0 ¥13.89 ¥19.84 ¥25.80 57
EPV ¥10.20 ¥11.25 ¥12.13 74
Multiples
P/E Multiple ¥15.14 ¥20.18 ¥25.23 63
P/S Multiple ¥8.06 ¥10.75 ¥13.43 58
P/B Multiple ¥11.70 ¥15.60 ¥19.49 55
EV/EBIT ¥16.14 ¥20.69 ¥25.24 66
EV/EBITDA ¥15.21 ¥19.45 ¥23.70 67
EV/Revenue ¥8.94 ¥11.70 ¥14.46 54
Asset-Based
NCAV (Graham) ¥2.64 ¥3.53 ¥5.27 54
Growth DCF
Growth DCF ¥11.96 ¥18.57 ¥30.32 77
Rev-Margin DCF ¥10.27 ¥17.42 ¥28.30 71
Economic Profit
Residual Income ¥5.26 ¥6.94 ¥18.46 67
ROIC Compounder ¥11.69 ¥14.81 ¥18.71 72
Growth Earnings
Growth-Adj P/E ¥18.93 ¥27.04 ¥35.16 67

Open the full fair value analysis →

Notify me when 300685 reaches fair value

Put 300685 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 77/100

Of which business quality 76 · Market factors (momentum, volatility) 47

Profitability 72
Margins and returns on capital today
Quality Growth 59
Are margins and returns improving?
Cashflow 77
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 54
Disciplined investing over empire-building
Low Volatility 75
Calm price path (market factor)
Momentum 40
Price trend over the last 3–12 months (market factor)
52W Momentum 28
Distance to the 52-week high (market factor)
Net Issuance 81
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 92/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+8.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.5%
Start year 2020 (pandemic). Over 10 years: +21.1% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.4%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+17.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+14.9%
Dividend (yield on the price)2.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.15% vs 29%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.28% → 35%
Start year 2020 (pandemic)

Growth Forecast

Price in line with expectations
The price assumes more growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+14.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+12.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +12.2% a year for the price and +10.4% for the forecasts.
Forecast 2026 (sales)+17.0%
Forecast 2027 (sales)+13.2%
Projected 2028 (sales)+11.8%
Projected 2029 (sales)+10.4%
Projected 2030 (sales)+9.0%

Watch 300685, get fair value alerts →

Compare Amoy Diagnostics Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 141 stocks

Beats the industry median on 10/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 77 · Top 25%
Fair Value upside +10% · Top 25%
Profitability
Return on equity (TTM) 18% · Top 25%
Return on assets 11% · Top 25%
Net margin (TTM) 30% · Top 25%
Operating margin (TTM) 39% · Top 25%
Growth and dividend
Revenue growth −4% · Below median
Dividend yield (TTM) 2.3% · Above median
Balance sheet
Debt / equity 0.05× · Below median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/E (TTM) 22.4× · Cheaper than median
P/B 3.85× · Pricier than median
P/S (TTM) 6.68× · Priciest 25%
P/FCF 4.0× · Cheaper than median
EV/EBITDA 15.8× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)47 · sector 0
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)72 · sector 9
HEALTH (low debt)98 · sector 95
DIVIDEND (yield)45 · sector 30

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $658.52 $682.58 +4%
Danaher Corporation DHR $221.09 $207.76 −6%
WuXi AppTec Co 2359 HK$207.60 HK$228.36 +10%
Lonza Group LONN CHF 562.80 CHF 151.69 −73%
IDEXX Laboratories, Inc IDXX $521.50 $495.84 −5%
Agilent Technologies, Inc A $167.26 $63.90 −62%
Waters Corporation WAT $425.74 $106.31 −75%
IQVIA Holdings IQV $270.09 $295.80 +10%
Illumina, Inc ILMN $247.46 $272.21 +10%
Mettler-Toledo International Inc MTD $1,491 $635.75 −57%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Amoy Diagnostics Co Ltd · Fair Value
¥21.92 +9%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Amoy Diagnostics Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/300685

Frequently asked questions

Is Amoy Diagnostics Co Ltd (300685) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥21.92 versus a price of ¥19.93, about +10% upside (undervalued).
What is the fair value of 300685?
Our model-based fair value for Amoy Diagnostics Co Ltd is ¥21.92 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥19.93.
What is the quality score of 300685?
Amoy Diagnostics Co Ltd has a Quality Score of 77/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Amoy Diagnostics Co Ltd (300685)?
Our model-based price target is the fair value of ¥21.92 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario ¥15.17, optimistic scenario ¥36.81. It is a calculation from audited fundamentals, not an analyst target.
What is the Amoy Diagnostics Co Ltd stock forecast for 2026?
Our models put fair value at ¥21.92, about +10% upside versus a price of ¥19.93 (undervalued). Cautious scenario ¥15.17, optimistic scenario ¥36.81. The calculation is refreshed regularly with new filings.
What is the revenue of Amoy Diagnostics Co Ltd (300685)?
Amoy Diagnostics Co Ltd reported trailing-twelve-month revenue of about 1.2B CNY (latest available figure, as of Sep 24, 2026).
Does Amoy Diagnostics Co Ltd pay a dividend?
Amoy Diagnostics Co Ltd currently shows a dividend yield of about 2.26% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Amoy Diagnostics Co Ltd (300685)?
For today's price to be fair in a discounted-cash-flow model, Amoy Diagnostics Co Ltd would have to grow free cash flow by +14.1 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +10.5 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 300685 use?
Our models discount Amoy Diagnostics Co Ltd at 10.4 %: a base by market capitalisation (small), damped by beta 0.36, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Amoy Diagnostics Co Ltd that is +14.1 % per year a year over ten years, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Amoy Diagnostics Co Ltd (300685) delivered so far?
Over the past 5 years revenue at Amoy Diagnostics Co Ltd grew +10.5 % a year. The price currently implies +14.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Amoy Diagnostics Co Ltd (300685) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Amoy Diagnostics Co Ltd (+14.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Amoy Diagnostics Co Ltd (300685)?
The free-cash-flow yield on the price is 3.72 %: that much free cash flow Amoy Diagnostics Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Amoy Diagnostics Co Ltd (300685)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Amoy Diagnostics Co Ltd it is ¥21.92 per share (as of Sep 24, 2026), against a price of ¥19.93. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Amoy Diagnostics Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 300685 trades below its calculated fair value: price ¥19.93, fair value ¥21.92, a gap of about +10% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300685?
No. The price is what the market pays today (¥19.93); the fair value is what the company's own numbers justify (¥21.92). For Amoy Diagnostics Co Ltd the two are ¥1.99 per share apart. That gap is exactly why we show both numbers side by side.
How much is Amoy Diagnostics Co Ltd worth?
The market values Amoy Diagnostics Co Ltd at about 7.9B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥19.93; our models calculate a fair value of ¥21.92 per share.
What do the bullish and bearish scenarios say about 300685?
Our models span a range for Amoy Diagnostics Co Ltd: cautious scenario ¥15.17, base ¥21.92, optimistic ¥36.81 per share (as of Sep 24, 2026, price ¥19.93). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 300685?
Amoy Diagnostics Co Ltd trades at a price-to-earnings ratio of 22.4 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥21.92 is built from several models across several years. Other multiples: P/B 3.9, P/S 6.7, EV/EBITDA 15.8.
How solid is the balance sheet of Amoy Diagnostics Co Ltd (300685)?
Balance-sheet figures for Amoy Diagnostics Co Ltd (as of Sep 24, 2026): return on equity 17.9%, debt of 0.05 per unit of equity. They feed the Quality Score of 77/100, which measures business quality independently of the share price.
How far is 300685 from its 52-week high?
Amoy Diagnostics Co Ltd trades at ¥19.93, about 14% below its 52-week high of ¥23.29 and 23% above the low of ¥16.18 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of ¥21.92 is for.
Which stocks are comparable to Amoy Diagnostics Co Ltd?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Amoy Diagnostics Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price ¥19.93, calculated fair value ¥21.92 (+10%), Quality Score 77/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300685 calculated?
We run Amoy Diagnostics Co Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥21.92, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Amoy Diagnostics Co Ltd currently trades 10 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Amoy Diagnostics Co Ltd (300685)?
The closing price on Sep 22, 2026 was ¥19.93. Our model-based fair value is ¥21.92, about +10% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Amoy Diagnostics Co Ltd right now?
A fairly wide model range (¥15.17 to ¥36.81) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Amoy Diagnostics Co Ltd (300685) come from?
Earnings per share at Amoy Diagnostics Co Ltd grew +29.6 % a year from 2013 to 2024. Broken into its drivers: revenue per share +23.9 %, EBIT margin +8.0 %, tax rate +1.1 %, residual (interest, one-offs) −4.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Amoy Diagnostics Co Ltd

How large is the market capitalisation of Amoy Diagnostics Co Ltd (300685)?
The market capitalisation of Amoy Diagnostics Co Ltd is 7.9B CNY (≈ $1.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Amoy Diagnostics Co Ltd (300685)?
The price-to-sales ratio of Amoy Diagnostics Co Ltd is 6.69 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Amoy Diagnostics Co Ltd (300685)?
Earnings per share at Amoy Diagnostics Co Ltd are ¥0.8900 (price ÷ EPS = P/E 22.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Amoy Diagnostics Co Ltd (300685)?
The dividend yield of Amoy Diagnostics Co Ltd is 2.3% (payout 50.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Amoy Diagnostics Co Ltd (300685)?
The net margin of Amoy Diagnostics Co Ltd is 29.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Amoy Diagnostics Co Ltd (300685)?
The return on equity (ROE) of Amoy Diagnostics Co Ltd is 17.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Amoy Diagnostics Co Ltd (300685)?
On an EBIT basis the return on assets of Amoy Diagnostics Co Ltd is 16.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Amoy Diagnostics Co Ltd (300685)?
The operating margin of Amoy Diagnostics Co Ltd is 38.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Amoy Diagnostics Co Ltd (300685)?
Revenue at Amoy Diagnostics Co Ltd is growing −4.3% versus a year earlier (3y avg +12.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Amoy Diagnostics Co Ltd (300685)?
Earnings per share at Amoy Diagnostics Co Ltd are growing −4.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Amoy Diagnostics Co Ltd (300685) hold?
Amoy Diagnostics Co Ltd holds more cash than debt, 820M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Amoy Diagnostics Co Ltd in the live analysis

One click puts Amoy Diagnostics Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.